
# 705 Supplemental Information

### 706 Summary

<sup>707</sup> Below find additional treatments of sub-topics which may be
 <sup>708</sup> relevant to material offered in main text. These include a supple <sup>709</sup> mental discussion, methods and results.

# The initial choice of traits for the study of epistasis: drugless growth, IC<sub>50</sub>, and intracellular abundance

The biology underlying how the measured traits (drugless 712 growth, IC<sub>50</sub>, intracellular abundance) relate to drug resistance 713 is well-studied and reasonably intuitive. We initially studied 714 all three traits, as all are present in analytical equations that de-715 scribe the components of drug resistance (Rodrigues et al. 2016). 716 Drugless growth rate is synonymous to fitness of an organism in 717 the absence of drug. In order to be resistant to Trimethoprim, a 718 given microbe must demonstrate some baseline ability to grow. 719 In this system, we expect drugless growth to be lower and less 720 variant across genotypic contexts, indicative of a trait with rela-72 tively little higher-order epistasis. This expectation comes from 722 our knowledge of the biology of the system: plasmids were 723 used to express the DHFR mutants in the background bacterial 724 strain in order to measure abundance, *IC*<sub>50</sub> and drugless growth. 725 726 In almost all strains, the simple presence of the plasmid was burdensome to the background strain, almost independent of 72 which species of DHFR was being expressed, or what the PQC 728 genetic background was. Consequently, the drugless growth 729 trait provides something analogous to a negative control, a trait 730 that should be relatively bereft of higher-order epistasis, as all 73 bacterial strains carrying plasmid had a similar low growth rate. 732



**Figure S1**. Based on the Bayesian inference criterion (BIC), drugless growth rate has no higher-order interactions, and very few significant main effect drivers. This is in stark contrast to the  $IC_{50}$  and abundance phenotypes, both which of contain several higher-order interactions.

733

#### 734 Measurement of drugless growth rate

Bacterial cultures were grown overnight (37 °C) in M9 minimal
medium were normalized to an OD of 0.1 with fresh medium.
When appropriate, GroEL overexpression and/or increase in
DHFR concentrations were induced by adding arabinose and
IPTG immediately after normalization. After additional growth
during 5-6 hours a new normalization to an OD = 0.1 was performed before inoculation of 96-well plates (1/5 dilution) con762

- taining M9 medium. Growth was quantified by integration of
- <sup>743</sup> the area under the growth curve.

744

745

746

747

748

749

750


751

752

756


## Inference of linear genotype-phenotype maps

Epistasis can be erroneously inferred when the underlying genotype does not map linearly to the corresponding phenotypic effects. We checked for potential non-linearity of the genotypephenotype map by evaluating the relationship between the observed phenotypes and the predicted values from an additive model ( $Y \sim S + C + P21L + A26T + L28R$ ), since deviations from a one-to-one relationship between these two would suggest the presence of 'global' epistasis (as in Sailer and Harms (2017); Otwinowski *et al.* (2018)). We found no strong evidence of non-linear genotype-phenotype maps in either  $IC_{50}$  or protein abundance (Figure S2). The best-fit polynomial splines are close to the identity line, especially for  $IC_{50}$ .



**Figure S2**. Relationship between the (A) abundance and (B)  $IC_{50}$  observed and their values predicted by an additive linear model. The blue lines represent cubic splines fit to the points, the identity line is dashed.

To verify that our overall conclusions are not affected by the choice of phenotypic scale, we linearized the observed abundance (back-transforming from Box-Cox transformation; see Sailer and Harms (2017) Eq.2) and used these values in a new regularized regression analysis. We found no qualitative differences in the results (Figure S3).



**Figure S3**. There are only small quantitative differences between the coefficients inferred for abundance (horizontal axis, corresponds to results in main text, Figure 3) and those inferred using a linearized version of the same phenotype.

Notes on the biochemistry and biophysics of the study system 815 763 816 Prior studies have established that the deleterious effect of desta-764 817 bilizing DHFR mutations can be alleviated by the action of the 765 818 protein quality control(PQC) machinery (Bershtein et al. 2013). 766 819 Specifically, GroEL/ES chaperonins and Lon proteases were 767 820 shown to be major modulators of the total intracellular DHFR 768 abundance, acting upon partially unfolded protein intermedi-769 ates to either promote folding or proteolytic degradation, respec-821 770 tively. The impact of PQC background on fitness is particularly 822 771 772 relevant in cases where drug-resistance DHFR mutations are 823 associated with stability trade-offs (Rodrigues et al. 2016) and in 773 824 scenarios of horizontal gene transfer (Bershtein et al. 2015). 774 825

Though the  $IC_{50}$  values utilized in this study are laboratory <sup>826</sup> derived, prior studies have identified relationships between  $IC_{50}$ 827 and biochemical and biophysical parameters. Rodrigues et al. 828 Rodrigues *et al.* (2016) described such an analytical expression: 829

$$IC_{50} = rac{1}{lphaeta} rac{k_{cat}^n}{k_m^n} rac{Abundance}{\gamma ANS} K_i^n - rac{1}{lpha} K_i^n$$

We do not use the above equation in this study, and consequently, 775 are providing it in the supplemental information only to high-834 776 light that a mathematical relationship has been proposed that 777 835 links these traits analytically. Mechanistically, we can most sim-778 836 plistically summarize their relationship this way: in order for 779 837 a population of bacteria to grow in the presence of trimetho-780 838 781 prim (which  $IC_{50}$  is a presumptive measure of), they must be functional cells that can growth without drug and must pro-782 840 duce enough DHFR (the target of Trimethoprim) such that the 783 841 normal metabolic functions of DHFR are performed. If only 784 842 small amounts of DHFR are produced, then we can expect low 785 843 amounts of drug to sufficiently limit growth (low  $IC_{50}$ ). 786 844

#### Regarding antifolates and the evolution of resistance 787

The study focused on dihydrofolate reductase, an essential en-847 788 zyme and target of antibiotics. Though the focus of the study 848 789 was more general (about resolving epistastic effects across geno- 849 790 typic contexts), the specific biological problem of antifolate re- 850 791 sistance did warrant a more detailed examination, which we 851 792

provide here. Antifolates are used clinically as treatments for 793 a wide range of diseases, ranging from bacteria, to protozoal diseases and as anticancer agents (Bershtein et al. 2015; Schnell 795 et al. 2004; Kompis et al. 2005; Liu et al. 2013). These compounds 796 interfere with one of two steps in the *de novo* biosynthetic path-797 way of tetrahydrofolate (THF), essential for the production of 798 purines and of several amino acids. The genetic basis for antifo-799 late resistance evolution in bacteria lies in a small number of 800 missense mutations in several genes, one of which is dihydrofo-802 late reductase (DHFR). Previous studies had identified that three mutations (A26T, P21L, L28R) that are often found in present var-803 ious combinations and have an effect on trimethoprim resistance 804 (an antifolate) in E. coli (Toprak et al. 2012). 805

#### Regarding the implications of the results for the study of an-806 tibiotic resistance 807

We should very briefly highlight the results in light of their implications for the study of drug resistance. As previously described, the study system was bacterial DHFRs, the protein target of antifolate drugs. For future efforts at resistance management, we should be clear about what contextual details influence the phenotypic consequences of resistance-associated SNPs before we fully conclude how a given set of SNPs drives resistance evolution in nature. For example, we should be mindful of how off-target mutations (like the ones that constitute species background and proteostasis machinery in this study) might influence patterns of resistance. Related questions about the evolution of resistance are the object of current inquiry from several of the co-authors of this study.

# Study limitations

794

801

808

809

810

811

812

813

814

830

831 832

833

845

846

As with any study making a general claim about an important problem (epistasis in this case), there is the potential critique that the results of a study "do not generalize." We remind the authors of such criticism that the study system focused on traits related to antibiotic resistance, a phenotype with biomedical implications. That being the case, even if the methods and results were only relevant to the problem of antibacterial resistance to antifolate compounds (and did not generalize further), we would consider the findings to be relevant for several scientific and biomedical communities. We are, however, confident that the methods and results are reflective of phenomena present in complex traits across the biosphere.

#### Minor notes on methods to detect epistasis

Several studies that measure epistasis utilize data sets where multiple mutations are constructed in all possible combinations, often in the guise of a graph called a fitness (or adaptive) landscape (Greene and Crona 2014; Ferretti et al. 2016; Ogbunugafor et al. 2016; Sailer and Harms 2017; Weinreich et al. 2018). For data sets where variation at sites of interest is biallelic, these combinatorial sets are composed of  $2^L$  mutations, where L is the number of different loci being examined. The mutations that compose the combinatorial set might have originated from experimental evolution (Chou et al. 2014; Toprak et al. 2012) or from field surveys (Projecto-Garcia et al. 2013; Domyan et al. 2014; Natarajan et al. 2018). Regardless of their source, several methods have been introduced to detect the presence of higher-order interactions between mutations in data sets similar to the one in this study. One notable method involves the Fourier-Walsh transformation to generate terms corresponding to epistatic interactions between biallelic sites in a fitness graph (Weinreich et al. 2013;

- Poelwijk *et al.* 2016; Weinreich *et al.* 2018). Others have used regression methods similar to the ones in this study (Otwinowski
- and Plotkin 2014; Poelwijk and Ranganathan 2017).
- As with several of these methods, the epistatic decomposition
- methods utilized in this study incorporate experimental noise,
- do not require biallelic loci, and can accommodate missing data.
  The relaxing of the biallelic loci constraint is especially important
- for this study: while the individual SNP loci in the data set can be
- characterized as biallelic (P21L, A26T, L28R), the species context
- (Escherichia coli, Chlamydia muridarum, and Listeria grayi) and
- protein quality control genetic background (wild-type, GroEL+,
- and  $\Delta lon$ ) are each composed of three variants per locus.